Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose in haemodialysis-associated anaemia
ISRCTN95017029Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA) and chronic kidney disease (CKD), sponsored by CSL Vifor. Primary endpoints: Responder rate by haemoglobin increase and Correction of iron stores and haemoglobin. Started Jul 2003; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ISRCTN95017029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95017029.